亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

De Novo Purine Biosynthesis in Drug Resistance and Tumor Relapse of Childhood ALL

生物 癌症研究 遗传学 突变 核苷酸回收 嘌呤代谢 基因 核苷酸 生物化学 酶
作者
Hui Li,Benshang Li,Fan Yang,Cai‐Wen Duan,Yun Bai,Jun J. Yang,Jing Chen,Arend von Stackelberg,Hongzhuan Chen,Jingyan Tang,Adolfo A. Ferrando,Jinghui Zhang,Shengyue Wang,Renate Kirschner‐Schwabe,Bin‐Bing S. Zhou
出处
期刊:Blood [Elsevier BV]
卷期号:126 (23): 2627-2627 被引量:2
标识
DOI:10.1182/blood.v126.23.2627.2627
摘要

Abstract Background: Relapse is the leading cause of mortality in children with acute lymphoblastic leukemia (ALL). Studies have shown that most ALL cases are polyclonal at diagnosis and that genetic changes in individual subclones influence sensitity to therapy and subsequent clonal evolution during therapy; but the molecular details remain to be worked out. Among different pathways enriched for mutations at relapse, purine metabolism is particularly interesting for two reasons: first, thiopurines are widely used in the ALL combination chemotherapy regimens, and are prodrugs that are converted by the purine salvage pathway to cytotoxic metabolites. Second, de novo nucleotide biosynthesis is often upregulated in cancer cells, and it is believed that sufficient nucleotide pools are required to maintain genomic stability, could bypass oncogene-induced senescence and promote tumor progression1. Therefore, we focus our current study on de novo purine biosynthesis in drug resistance and tumor relapse of childhood ALL. Methods and Results: Using whole-exome sequencing, we identified relapse-specific mutations in the phosphoribosyl pyrophosphate synthetase 1 gene (PRPS1), which encodes a rate-limiting purine biosynthesis enzyme, in 24/358 (6.7%) relapsed childhood B cell ALL (B-ALL) cases. Targeted sequencing identified mutations in additional genes in de novo purine biosynthesis pathway, providing further genetic evidence for its importance in relapsed ALL. All individuals with PRPS1 mutation relapsed early on-treatment (P <0.001), having an inferior prognosis1. Using various functional assays, we demonstrated that rather than causing a simple gain-of-function effect, the mutations in PRPS1 resulted in the disruption of the normal feedback inhibition of purine synthesis, in which the enzyme remained active despite an increased concentration of nucleoside analogs. PRPS1 mutants increased synthesis of the nucleoside inosine monophosphate, its metabolite hypoxanthine (HX) and de novo purine biosynthesis intermediates (e.g. AICAR, SAICAR) in Reh cells. Increased intracellular HX can competively inhibit the conversion of thiopurines into their active metabolites. Furthermore, inhibition of de novo purine biosynthesis in vitro, either by CRISPR-Cas9 genome editing of de novo purine synthesis pathway genes (GART, ATIC etc.) or treatment with a pathway inhibitor lometrexol (GART inhibitor) alleviated the metabolic disturbance and drug resistance induced by PRPS1 mutations. Using ultra-deep sequencing of unique serial remission samples before clinical relapse, we noticed that the PRPS1 mutant allele fraction increased drastically before clinical relapse, suggesting rapid clonal expansion occurs after the acquisition of a PRPS1 mutation. Interestingly, we also noticed that PPRS1 mutation coexist with RAS mutation in many relapse cases and at single cell resolution. Functional analysis revealed that tumor cells which harbored RAS and PRPS1 double mutations are more drug resistant than those with RAS or PRPS1 mutation alone. Previous studies have shown that oncogenic RAS mutation can also induce various stress responses including oncogene-induced senensence and DNA damage response (DDR), which all could impede tumor cell proliferation during relapse. In vitro, we found PRPS1 mutation can release the replication and metabolic stress caused by RAS mutation, in addition to their role in thiopurine resistance. The PRPS1 mutants not only increase the nucleotide pools but also elevate purine biosynthesis intermediate AICAR, which can activate AMPK and reduce the RAS mutant-induced DDR. We are currently working on in vitro and in vivo models (including patient derived xenograft models) to further test the double mutant's effects on tumor-reinitiation and clonal evolution during ALL relapse. Conclusions: We demonstrated that negative feedback-defective PRPS1 mutants can drive de novo purine biosynthesis, which can exert drug resistance and reduce genomic instability during tumor relapse. Our study highlights the importance of de novo purine biosynthesis in the pathogenesis of relapse, and suggests a diagnostic approach to predicting early relapse and a therapeutic strategy to circumventing resistance in ALL. 1 Li et al. Negative feedback-defective PRPS1 mutants drivee thiopurine resistance in relapsed childhood ALL. Nature Medicine,21(6): 563-571 (2015) Disclosures No relevant conflicts of interest to declare.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cscgood完成签到,获得积分10
2秒前
8秒前
科研通AI65的应助被科研通管家采纳,获得10
8秒前
8秒前
Lucas的应助被科研通管家采纳,获得10
8秒前
小野完成签到,获得积分10
8秒前
爆米花的应助被科研通管家采纳,获得10
9秒前
clamdown完成签到,获得积分10
10秒前
愉快的惋庭完成签到,获得积分10
17秒前
华仔的应助被不要命的小火龙采纳,获得10
18秒前
18秒前
orixero的应助被呵呵采纳,获得10
26秒前
符聪发布了新的文献求助10
34秒前
34秒前
35秒前
呵呵发布了新的文献求助10
45秒前
天真的音完成签到,获得积分10
47秒前
ZDU完成签到 ,获得积分10
51秒前
syvshc的应助被00hello00采纳,获得10
53秒前
null的应助被初景采纳,获得10
58秒前
NexusExplorer的应助被爱听歌笑寒采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
呵呵发布了新的文献求助10
1分钟前
1分钟前
1分钟前
CAOHOU给yyyy的求助进行了留言
1分钟前
智慧树发布了新的文献求助10
1分钟前
爆米花的应助被00hello00采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
赘婿的应助被牛肉面采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
yangbing123发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195122
求助须知:如何正确求助?哪些是违规求助? 9580886
关于积分的说明 21872832
捐赠科研通 7795040
什么是DOI,文献DOI怎么找? 3437934
关于科研通互助平台的介绍 2561228
邀请新用户注册赠送积分活动 2484609